诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

盘前交易 12-26 07:32:41 EST

52.56

+0.95

+1.84%

盘前52.85

+0.29+0.55%

07:24 EST

最高53.63	最低52.00	成交量1,930万
今开52.85	昨收51.61	日振幅3.16%
总市值2,333亿	流通市值1,676亿	总股本44.39亿
成交额10.17亿	换手率0.61%	流通股本31.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":52.56,"timestamp":1766599200000,"preClose":51.61,"halted":0,"volume":19300102,"hourTrading":{"tag":"盘前","latestPrice":52.85,"preClose":52.56,"latestTime":"07:24 EST","volume":11158,"amount":589239.9878679999,"timestamp":1766751855012},"delay":0,"floatShares":3187922885,"shares":4439052849,"eps":3.665526,"marketStatus":"盘前交易","change":0.95,"latestTime":"12-26 07:32:41 EST","open":52.85,"high":53.63,"low":52,"amount":1017385383.82698,"amplitude":0.031583,"askPrice":52.83,"askSize":10,"bidPrice":52.8,"bidSize":36,"shortable":3,"etf":0,"ttmEps":3.665526,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766759400000},"marketStatusCode":1,"adr":1,"adrRate":1,"listingDate":363499200000,"exchange":"NYSE","adjPreClose":52.56,"dividendRate":0.032112,"preHourTrading":{"tag":"盘前","latestPrice":52.85,"preClose":52.56,"latestTime":"07:24 EST","volume":11158,"amount":589239.9878679999,"timestamp":1766751855012},"postHourTrading":{"tag":"盘后","latestPrice":52.6399,"preClose":52.56,"latestTime":"16:59 EST","volume":917503,"amount":48227451.5198,"timestamp":1766613595532},"volumeRatio":1.583248352690455,"optionData":{"bulkOrders":[{"symbol":"NVO","call":false,"expireDate":1768539600000,"strike":"80.0","timestamp":1766597717552,"price":27.25,"volume":3260,"amount":8883500,"type":"-"},{"symbol":"NVO","call":false,"expireDate":1768539600000,"strike":"80.0","timestamp":1766596084141,"price":25.99,"volume":2335,"amount":6068665,"type":"-"}]},"impliedVol":0.4293,"impliedVolPercentile":0.1165},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"2594261698","title":"诺和诺德长效生长激素诺泽优®正式在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2594261698","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594261698?lang=zh_cn&edition=full","pubTime":"2025-12-26 14:44","pubTimestamp":1766731472,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BZ1G4Q59.USD","BK4532","BK4007","LU0154236417.USD","BK4585","IE00BKVL7J92.USD","LU1093756325.SGD","NVO","BK4588","LU1093756168.USD","BK4599"],"gpt_icon":0},{"id":"2594650232","title":"RNAi药物七年突围：从黑暗到百亿市场的“沉默革命”","url":"https://stock-news.laohu8.com/highlight/detail?id=2594650232","media":"佰傲谷BioValley","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594650232?lang=zh_cn&edition=full","pubTime":"2025-12-26 12:03","pubTimestamp":1766721799,"startTime":"0","endTime":"0","summary":"今年，美国FDA批准了2款siRNA新药，至此全球已有8款RNAi产品获得监管批准。这两款siRNA药物是FDA批准的唯二两款治疗原发性高草酸尿症1型的药物。目前，诺和诺德尚未公布nedosiran的独立销售额数据。该批准也被视为RNAi开始从罕见病走向大品种治疗的标志性事件。这是FDA对于RNAi降脂的第二次批准。小结实际上，siRNA药物的销售额连年增长，已经成为大型生物制药企业都关注的赛道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251226122839a6d11ae0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251226122839a6d11ae0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4153","TG","LDHA","NVO","BK4090"],"gpt_icon":0},{"id":"2594238935","title":"被礼来压制两年后，诺和诺德如何反攻：“向特朗普低头”换取关税豁免，以利润换速度抢跑新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2594238935","media":"华尔街见闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594238935?lang=zh_cn&edition=full","pubTime":"2025-12-25 15:56","pubTimestamp":1766649401,"startTime":"0","endTime":"0","summary":"诺和诺德正以降价换取美国关税豁免与监管提速，旨在通过抢占口服减肥药先机及挤压仿制药市场来重夺主导权。此举虽短期可能压制利润，但为公司在关键窗口中阻击礼来、收复失地赢得了战略缓冲，并推动其估值进入深度修复阶段。","market":"other","thumbnail":"https://community-static.tradeup.com/news/e6d86fcd8831d3b323537bcea0bd75ad","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/e6d86fcd8831d3b323537bcea0bd75ad"],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3762061","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3762061","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","LLY"],"gpt_icon":1},{"id":"2593470722","title":"诺和诺德盘中异动 早盘快速拉升3.55%报53.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593470722","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593470722?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:38","pubTimestamp":1766587108,"startTime":"0","endTime":"0","summary":"北京时间2025年12月24日22时38分，诺和诺德股票出现异动，股价急速上涨3.55%。截至发稿，该股报53.44美元/股，成交量435.45万股，换手率0.10%，振幅1.95%。诺和诺德股票所在的制药行业中，整体涨幅为0.68%。诺和诺德公司简介：诺和诺德在全球品牌糖尿病治疗市场中占据大约三分之一的份额，是世界上领先的糖尿病护理产品供应商。诺和诺德还拥有一个生物制药部门，专注于治疗血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224223828a473c9d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"a66dd7b79b03178afcecfcf9296f90d3","theme_name":"🔥热榜No.60 · 诺和诺德股价因FDA批准口服减肥药大幅上涨","theme_type":2,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224223828a473c9d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","NVO","IE00BKVL7J92.USD","LU0154236417.USD","BK4532","IE00BZ1G4Q59.USD","LU1093756325.SGD","LU1093756168.USD","BK4588","BK4007","BK4585"],"gpt_icon":1},{"id":"2593471612","title":"司美格鲁肽，又一新适应症获批！","url":"https://stock-news.laohu8.com/highlight/detail?id=2593471612","media":"药通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593471612?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:19","pubTimestamp":1766567985,"startTime":"0","endTime":"0","summary":"12 月 22 日，药监局官网显示，司美格鲁肽注射液的心血管适应症上市申请获得批准，适用于降低已确诊为心血管疾病且 BMI≥27 kg/m2 成人患者的主要心血管不良事件的风险。此次心血管适应症的获批基于 SELECT 的主要结果。这一发现提示，无论体重降幅，使用司美格鲁肽均实现降低 MACE 风险的获益。司美格鲁肽是全球首个用于长期体重管理的GLP-1RA周制剂，今年前三季度大卖 254 亿美元，占诺和诺德总营收的 81.44%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224193758a6ca363c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224193758a6ca363c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4157","BK4532","LU1093756168.USD","NVO","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1093756325.SGD","BK4183","BK4588","BK4585","LU0154236417.USD","BK4599","BK4007"],"gpt_icon":1},{"id":"2593426794","title":"诺和诺德高剂量司美格鲁肽获EMA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2593426794","media":"DoNews","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593426794?lang=zh_cn&edition=full","pubTime":"2025-12-24 12:47","pubTimestamp":1766551622,"startTime":"0","endTime":"0","summary":"2024年7月9日，诺和诺德宣布其7.2mg司美格鲁肽的上市申请已获欧洲药品管理局（EMA）受理，适应症为体重管理。该申请基于III期STEP UP及STEP UP T2D两项临床研究的积极结果，评估了该剂量在减重及2型糖尿病患者中的疗效与安全性。若获批，该产品将成为更高剂量的新型肥胖治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224125122a6c8bee6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224125122a6c8bee6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4081","BK4599","LU1093756325.SGD","BK4532","BK4585","BK4588","NVO","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756168.USD","BK4007","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"1123443555","title":"期权大单 | 英伟达190美元CALL交易激增！诺和诺德看涨期权火爆，SOC暴涨反现看跌大单","url":"https://stock-news.laohu8.com/highlight/detail?id=1123443555","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123443555?lang=zh_cn&edition=full","pubTime":"2025-12-24 12:19","pubTimestamp":1766549959,"startTime":"0","endTime":"0","summary":"期权市场总成交量42,807,940张合约，其中看涨期权占比58%。12月26日到期的53美元的行权看涨期权交易量特别高，共有29,308份合约交易。$NVO 20251226 53.0 CALL$ 消息方面：美国FDA批准了诺和诺德的首款口服GLP-1减肥药，使其在与礼来的激烈竞争中抢得先机。临床数据显示其可帮助患者减重高达16.6%，并能降低心血管风险。$SOC 20260116 9.0 PUT$ 消息方面：公司表示，美国交通部管道和危险材料安全管理局已批准其拉斯弗洛雷斯管道系统的重启计划。","market":"us","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","NOW","SOC","NVDA"],"gpt_icon":1},{"id":"2593176440","title":"多个新药或新适应症获FDA批准，涉及肿瘤、肥胖、肺纤维化等领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2593176440","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593176440?lang=zh_cn&edition=full","pubTime":"2025-12-24 09:16","pubTimestamp":1766538973,"startTime":"0","endTime":"0","summary":"近日，多个创新药或新适应症获美国食品药品监督管理局批准，涉及罗氏、诺和诺德、勃林格殷格翰等。这些新药覆盖肿瘤、肥胖、肺纤维化等多个治疗领域，为患者带来了新的治疗选择。此次FDA批准基于关键性3期FIBRONEER-ILD临床试验结果，数据显示Jascayd可有效减缓PPF患者的肺功能下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224091748a6c7f4a2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224091748a6c7f4a2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ORR","BK4161","CR","NVO"],"gpt_icon":0},{"id":"2593445693","title":"美股成交额TOP20｜英伟达收涨3%，云业务战略进行重大调整；诺和诺德大涨逾7%，首款“口服版减肥神药”获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2593445693","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593445693?lang=zh_cn&edition=full","pubTime":"2025-12-24 06:15","pubTimestamp":1766528100,"startTime":"0","endTime":"0","summary":"周二美股成交额第1名英伟达收高3.01%，成交323.58亿美元。媒报道称，英伟达在公司CEO黄仁勋提出打造能与亚马逊AWS竞争的云服务愿景两年多后，对其云业务战略进行了重大调整，放弃了与这些大型云端公司正面竞争的计划。著名投资者凯西伍德及其旗下方舟投资公司持续减持特斯拉股票套现，而特斯拉股价于周一再创历史新高。　　监管记录显示，这笔交易于12月18日执行，并于12月22日通过一份Form 4文件披露，使陈福阳直接持有的股份减少至约595638股。","market":"sh","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b099eb465cc978dbf0999a63ae487ca3","theme_name":"🔥热榜No.59 · 凯西伍德抛售特斯拉股票套现2967万美元并持续减持引发市场关注","theme_type":2,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-24/doc-inhcvvxw0181516.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["NVO","NVDA","MSTR"],"gpt_icon":1},{"id":"1146844280","title":"异动解读 | 诺和诺德盘中大涨10.16%，首款口服减肥药Wegovy获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1146844280","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146844280?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:48","pubTimestamp":1766501314,"startTime":"0","endTime":"0","summary":"诺和诺德今日盘中大涨10.16%，引起市场广泛关注。此次股价异动主要得益于公司重磅口服减肥药Wegovy获得美国食品药品监督管理局批准。消息面上，FDA于12月22日批准了诺和诺德的首款GLP-1类口服减肥药Wegovy片剂，成为全球首个用于体重管理的口服GLP-1药物。此次批准让诺和诺德在与礼来的竞争中占据先机，分析师预计口服剂型将显著扩大患者覆盖范围，推动公司业绩增长。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a66dd7b79b03178afcecfcf9296f90d3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVO"],"gpt_icon":0},{"id":"2593415000","title":"诺和诺德盘中异动 股价大涨9.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593415000","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593415000?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:30","pubTimestamp":1766500205,"startTime":"0","endTime":"0","summary":"北京时间2025年12月23日22时30分，诺和诺德股票出现异动，股价大幅拉升9.50%。截至发稿，该股报52.67美元/股，成交量833.188万股，换手率0.19%，振幅0.00%。诺和诺德股票所在的制药行业中，整体涨幅为0.00%。诺和诺德公司简介：诺和诺德在全球品牌糖尿病治疗市场中占据大约三分之一的份额，是世界上领先的糖尿病护理产品供应商。诺和诺德还拥有一个生物制药部门，专注于治疗血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223223005a46f568d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"a66dd7b79b03178afcecfcf9296f90d3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223223005a46f568d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","LU0154236417.USD","BK4007","NVO","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4599","BK4532","BK4585","BK4588","LU1093756325.SGD"],"gpt_icon":0},{"id":"2593416300","title":"诺和诺德盘前涨幅扩大至10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593416300","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593416300?lang=zh_cn&edition=full","pubTime":"2025-12-23 22:27","pubTimestamp":1766500053,"startTime":"0","endTime":"0","summary":"诺和诺德盘前涨幅扩大至10%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512233599828932.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"a66dd7b79b03178afcecfcf9296f90d3","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512233599828932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BZ1G4Q59.USD","BK4532","IE00BKVL7J92.USD","BK4588","LU1093756168.USD","BK4585","LU1093756325.SGD","LU0154236417.USD","NVO","BK4007","BK4599"],"gpt_icon":0},{"id":"1156907195","title":"盘前｜以星航运、诺和诺德拉升，特朗普新计划助推亨廷顿英格尔斯工业","url":"https://stock-news.laohu8.com/highlight/detail?id=1156907195","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156907195?lang=zh_cn&edition=full","pubTime":"2025-12-23 20:26","pubTimestamp":1766492771,"startTime":"0","endTime":"0","summary":"美股三大指数在盘前交易时段微跌。","market":"us","thumbnail":"https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ed4ee39e6b0f45214393093d70ba81a8"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"458e11c8b4ffb4bd5a189ad6925c1428","theme_name":"🔥热榜No.78 · 美股盘前市场动态及个股表现分析","theme_type":2,"isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HII","ZIM","NVO"],"gpt_icon":1},{"id":"2593249419","title":"诺和诺德口服减肥药片获FDA批准，与礼来“减肥药之战”进入新回合","url":"https://stock-news.laohu8.com/highlight/detail?id=2593249419","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593249419?lang=zh_cn&edition=full","pubTime":"2025-12-23 19:30","pubTimestamp":1766489438,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"https://community-static.tradeup.com/news/e6d86fcd8831d3b323537bcea0bd75ad","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/e6d86fcd8831d3b323537bcea0bd75ad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a03a1a5280ce2755e027807f614a9d28","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LLY","NVO"],"gpt_icon":1},{"id":"1119754160","title":"盘前异动｜以星航运涨9%，诺和诺德涨超6%，特斯拉延续涨势","url":"https://stock-news.laohu8.com/highlight/detail?id=1119754160","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119754160?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:12","pubTimestamp":1766481160,"startTime":"0","endTime":"0","summary":"美股三大指数在盘前交易时段波动不大。","market":"us","thumbnail":"https://static.tigerbbs.com/3a33c23f8e5a366189f532d19af270ed","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3a33c23f8e5a366189f532d19af270ed"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZIM","TSLA","NVO"],"gpt_icon":0},{"id":"1143501633","title":"异动解读 | 诺和诺德盘前大涨7.05%，首款口服减肥药Wegovy获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1143501633","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143501633?lang=zh_cn&edition=full","pubTime":"2025-12-23 17:08","pubTimestamp":1766480909,"startTime":"0","endTime":"0","summary":"诺和诺德今日盘前大涨7.05%，引发市场广泛关注。此次股价飙升主要得益于其重磅口服减肥药Wegovy获得美国食品药品监督管理局批准。消息面上，FDA于12月22日批准了诺和诺德的首款GLP-1类口服减肥药Wegovy片剂，成为全球首个用于体重管理的口服GLP-1药物。此次批准让诺和诺德在与礼来的竞争中占据先机，分析师预计口服剂型将显著扩大患者覆盖范围，推动公司业绩增长。高盛预测，到2030年口服减肥药市场规模或达220亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ddb32471fd4f2e2e704679ce673a6020","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVO"],"gpt_icon":0},{"id":"2593495339","title":"欧洲股市小幅上涨STOXX600创历史新高 制药板块领涨诺和诺德飙升6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593495339","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593495339?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:39","pubTimestamp":1766479173,"startTime":"0","endTime":"0","summary":"（原标题：欧洲股市小幅上涨STOXX600创历史新高 制药板块领涨诺和诺德飙升6%）金吾财讯|欧洲股市周二小幅走高，STOXX50指数上涨0.1%，STOXX600指数上涨0.3%创下历史新高，在前一交易日小幅下跌后出现反弹。制药板块领涨大盘，诺和诺德股价飙升近6%，因其口服版减肥药Wegovy获得美国FDA批准上市。其他大型制药公司也录得上涨，阿斯利康上涨0.8%，诺华上涨0.7%，罗氏上涨0.6%。防御性板块包括电信和金融服务也为大盘走强做出贡献。另一方面，奢侈品板块承压，LVMH下跌0.1%，爱马仕下跌0.4%，开云集团下跌0.4%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223171221a6c548db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223171221a6c548db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1093756168.USD","BK4588","IE00BZ1G4Q59.USD","BK4585","NVO","BK4532","IE00BKVL7J92.USD","LU1093756325.SGD","BK4007","LU0154236417.USD","BK4599"],"gpt_icon":0},{"id":"2593609694","title":"诺和诺德欧股涨超7%，公司减肥口服药获美国批准。","url":"https://stock-news.laohu8.com/highlight/detail?id=2593609694","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593609694?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:05","pubTimestamp":1766477130,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a03a1a5280ce2755e027807f614a9d28","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1093756168.USD","BK4588","IE00BZ1G4Q59.USD","BK4585","NVO","BK4532","IE00BKVL7J92.USD","LU1093756325.SGD","BK4007","LU0154236417.USD","BK4599"],"gpt_icon":0},{"id":"2593469996","title":"2025生物制药5大失败临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2593469996","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593469996?lang=zh_cn&edition=full","pubTime":"2025-12-23 10:10","pubTimestamp":1766455833,"startTime":"0","endTime":"0","summary":"Biospace近日总结了生物制药领域在2025年五项代价高昂的临床失败，并分析了其引发的连锁反应。Alector与GSK于2021年7月达成合作，GSK投入预付款7亿美元，并承诺最高15亿美元的里程碑付款，以合作研发两款神经领域药物。双方2021年协议中的第二款药物nivisnebart目前处于II期研发阶段，用于治疗早期阿尔茨海默病。▌诺和诺德GLP-1药物阿尔茨海默适应症临床试验失利在神经科学领域折戟的还有诺和诺德。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223102629a46cc8bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223102629a46cc8bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GSK.UK","IE00B19Z3581.USD","LU0306806265.USD","LU0321505868.SGD","LU0154236417.USD","LU0456855351.SGD","LU1883839398.USD","LU1023059063.AUD","SGXZ57979304.SGD","IE00BKVL7J92.USD","BK4007","BK4550","IE00BLSP4239.USD","LU0122379950.USD","LU0234572021.USD","LU0321505439.SGD","LU1894683348.USD","PFE","SG9999011175.SGD","LU1057294990.SGD","SG9999013999.USD","ALEC","IE00BLSP4452.SGD","IE0002270589.USD","LU1066051498.USD","LU0985481810.HKD","IE00BBT3K403.USD","BK4585","BMY","BK4533","IE00B19Z3B42.SGD","BK4139","BK4213","LU0225771236.USD","LU0289739699.SGD","BK4588","LU0058720904.USD","LU1093756325.SGD","NVO","IE00BZ1G4Q59.USD","LU0306807586.USD","GSK","LU0225284248.USD","BK4581","SG9999003800.SGD","SG9999001176.SGD","BK4592","LU0170899867.USD","LU1894683264.USD","SG9999002232.USD","BK4532","BK4599","LU1093756168.USD","IE000M9KFDE8.USD","LU1066053197.SGD","SG9999002224.SGD","BK4568","SG9999001176.USD","BK4534","LU1829250122.USD","LU0868494617.USD"],"gpt_icon":1},{"id":"2593546606","title":"同日多家药企新药在华获批上市，自研罕见病创新药引人注目","url":"https://stock-news.laohu8.com/highlight/detail?id=2593546606","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593546606?lang=zh_cn&edition=full","pubTime":"2025-12-23 09:44","pubTimestamp":1766454240,"startTime":"0","endTime":"0","summary":"2025年药企研发热情和创新活力强劲，12月15日至21日，CDE批准超20款1类创新药临床试验申请，12月22日多家药企新药在华获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223095030a6c3a87e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223095030a6c3a87e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","LU1093756168.USD","GSK","MRK","BK4532","NVO","BK4599","BK4585","LU0154236417.USD","LU1093756325.SGD","BK4588","BK4007","IE00BKVL7J92.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":0.1003},{"period":"1month","weight":0.1688},{"period":"3month","weight":-0.0621},{"period":"6month","weight":-0.2328},{"period":"1year","weight":-0.3984},{"period":"ytd","weight":-0.389}],"compareEarnings":[{"period":"1week","weight":0.0283},{"period":"1month","weight":0.0324},{"period":"3month","weight":0.0491},{"period":"6month","weight":0.1227},{"period":"1year","weight":0.1481},{"period":"ytd","weight":0.178}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球医疗保健公司，也是糖尿病和肥胖症护理领域的全球领导者。该公司拥有广泛的糖尿病和肥胖症护理以及罕见疾病产品组合，包括用于治疗糖尿病和肥胖症的胰高血糖素样肽-1(GLP-1)受体激动剂、现代胰岛素和人胰岛素。","yearOnYearQuotes":[{"month":1,"riseRate":0.522727,"avgChangeRate":0.119015},{"month":2,"riseRate":0.613636,"avgChangeRate":0.028062},{"month":3,"riseRate":0.454545,"avgChangeRate":0.006986},{"month":4,"riseRate":0.613636,"avgChangeRate":0.01505},{"month":5,"riseRate":0.555556,"avgChangeRate":0.018382},{"month":6,"riseRate":0.688889,"avgChangeRate":0.026171},{"month":7,"riseRate":0.488889,"avgChangeRate":-0.001692},{"month":8,"riseRate":0.533333,"avgChangeRate":0.006145},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.002979},{"month":10,"riseRate":0.488889,"avgChangeRate":-0.004606},{"month":11,"riseRate":0.6,"avgChangeRate":0.026574},{"month":12,"riseRate":0.733333,"avgChangeRate":0.049513}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}